NCT05152420View on ClinicalTrials.gov

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

February 3, 2023

Study Completion Date

February 3, 2023

Conditions

Coagulation Disorder

Interventions

DRUG

VMX-C001

VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs

DRUG

Placebo

VMX-C001 matched placebo

DRUG

Apixaban

FXa Inhibitor

DRUG

Rivaroxaban

FXa Inhibitor

DRUG

Edoxaban

FXa Inhibitor

Trial Locations (1)

9713 GZ

QPS Netherlands B.V., Groningen

All Listed Sponsors

lead

VarmX B.V.

INDUSTRY

NCT05152420 - Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects | Biotech Hunter | Biotech Hunter